CN102079699B - 丙戊酸钠的新晶型及其制备方法和用途 - Google Patents
丙戊酸钠的新晶型及其制备方法和用途 Download PDFInfo
- Publication number
- CN102079699B CN102079699B CN 201110038689 CN201110038689A CN102079699B CN 102079699 B CN102079699 B CN 102079699B CN 201110038689 CN201110038689 CN 201110038689 CN 201110038689 A CN201110038689 A CN 201110038689A CN 102079699 B CN102079699 B CN 102079699B
- Authority
- CN
- China
- Prior art keywords
- sodium valproate
- hours
- constant temperature
- warming
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 title claims abstract description 112
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title claims abstract description 111
- 229940084026 sodium valproate Drugs 0.000 title claims abstract description 111
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 239000013078 crystal Substances 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 62
- 238000010792 warming Methods 0.000 claims description 52
- 238000002347 injection Methods 0.000 claims description 47
- 239000007924 injection Substances 0.000 claims description 47
- 238000001914 filtration Methods 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- 238000007710 freezing Methods 0.000 claims description 13
- 230000008014 freezing Effects 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 239000012982 microporous membrane Substances 0.000 claims description 11
- 238000012546 transfer Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 76
- 238000004108 freeze drying Methods 0.000 description 53
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 15
- 238000001035 drying Methods 0.000 description 13
- 231100000284 endotoxic Toxicity 0.000 description 13
- 230000002346 endotoxic effect Effects 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 13
- 230000004580 weight loss Effects 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 238000005352 clarification Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000002050 diffraction method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000005265 energy consumption Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010034759 Petit mal epilepsy Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000028316 focal seizure Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110038689 CN102079699B (zh) | 2010-02-11 | 2011-02-11 | 丙戊酸钠的新晶型及其制备方法和用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201019087032.9 | 2010-02-11 | ||
CN201019087032 | 2010-02-11 | ||
CN 201110038689 CN102079699B (zh) | 2010-02-11 | 2011-02-11 | 丙戊酸钠的新晶型及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102079699A CN102079699A (zh) | 2011-06-01 |
CN102079699B true CN102079699B (zh) | 2013-09-04 |
Family
ID=44085924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110038689 Active CN102079699B (zh) | 2010-02-11 | 2011-02-11 | 丙戊酸钠的新晶型及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102079699B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102531878B (zh) * | 2011-02-25 | 2014-08-20 | 四川科瑞德凯华制药有限公司 | 丙戊酸钠化合物及其制备方法和用途 |
CN105017007B (zh) * | 2014-04-16 | 2019-04-16 | 四川科瑞德制药股份有限公司 | 一种丙戊酸钠化合物 |
CN105380935B (zh) * | 2014-09-03 | 2018-04-03 | 长春海悦药业股份有限公司 | 一种丙戊酸钠药物组合物 |
CN105640873A (zh) * | 2014-12-05 | 2016-06-08 | 四川科瑞德制药有限公司 | 一种丙戊酸钠注射液及其制备方法和用途 |
-
2011
- 2011-02-11 CN CN 201110038689 patent/CN102079699B/zh active Active
Non-Patent Citations (2)
Title |
---|
GjorgiPetrusevski et al..Solid-state forms of sodium valproate |
Solid-state forms of sodium valproate, active component of the anticonvulsant drug epilim.;Gjorgi Petrusevski,et al.;《Chem Med Chem 》;2008;第3卷(第9期);1377-1386 * |
Also Published As
Publication number | Publication date |
---|---|
CN102079699A (zh) | 2011-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102079699B (zh) | 丙戊酸钠的新晶型及其制备方法和用途 | |
CN102327238A (zh) | 一种注射用左卡尼汀组合物及其制备方法 | |
CN103304471B (zh) | 一种甲磺酸罗哌卡因化合物、其制备方法及其药物组合物 | |
CN104109124A (zh) | 卡博替尼·0.5苹果酸盐的晶体 | |
CN104434819B (zh) | 注射用乙酰谷酰胺粉针剂药物组合物和制法 | |
CN102603510B (zh) | 丙戊酸钠的晶型及其制备方法和用途 | |
CN102796078B (zh) | 一种泮托拉唑化合物、制备方法及其药物制剂 | |
CN102367229B (zh) | 一种二乙酰氨乙酸乙二胺化合物及其药物组合物 | |
CN103214382B (zh) | 一种盐酸甲氯芬酯化合物及其药物组合物 | |
CN110054606B (zh) | 一种二氢杨梅素-盐酸黄连素药物共晶及制备方法 | |
CN104721154B (zh) | 注射用谷氨酸诺氟沙星冷冻干燥粉针剂药物组合物 | |
CN104086531B (zh) | 一种埃索美拉唑钠化合物及其药物组合物 | |
CN102846561A (zh) | 一种供注射用的奥扎格雷钠药物组合物 | |
CN102258507A (zh) | 含有布洛芬的药物组合物及其制备方法和应用 | |
CN100509787C (zh) | 吡硫醇的新的药学上可接受的盐及其制备方法 | |
CN106924195B (zh) | 一种注射用紫杉醇脂质体组合物的冻干工艺 | |
CN103059000A (zh) | 一种新型奥美拉唑钠化合物及其药物组合物 | |
CN104109128A (zh) | 卡博替尼苹果酸盐及其制备方法 | |
CN109125287A (zh) | 一种普瑞巴林片剂及其制备方法 | |
CN103505408A (zh) | 一种奥拉西坦葡萄糖/氯化钠注射液的制备方法 | |
CN101121696B (zh) | 吡硫醇的金属盐及其水合物 | |
CN106336364A (zh) | 十四烷基硫酸钠晶型及其制备方法、应用和含其的药物组合物 | |
CN102424688B (zh) | 甲磺酸左旋尤利沙星晶体及其制备方法和用途 | |
CN107397722B (zh) | 注射用(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺冻干粉及其制备方法 | |
CN104510708B (zh) | 一种米铂冻干制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: KERUIDE PHARMACEUTICAL CO., LTD., SICHUAN Free format text: FORMER OWNER: CHENGDU CREDIT PHARMACEUTICAL INVESTMENT CO., LTD. Effective date: 20130808 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 646104 LUZHOU, SICHUAN PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130808 Address after: 646104 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Applicant after: Keruide Pharmaceutical Co., Ltd., Sichuan Address before: 4, building 2, building 8, 610041, hi tech Road, hi tech Zone, Sichuan, Chengdu Applicant before: Chengdu Credit Pharmaceutical Investment Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20110601 Assignee: Chengdu Nuodikang Biological Pharmaceutical Co., Ltd. Assignor: Keruide Pharmaceutical Co., Ltd., Sichuan Contract record no.: 2014510000018 Denomination of invention: New crystal form for sodium valproate and preparation method and usage thereof Granted publication date: 20130904 License type: Exclusive License Record date: 20140324 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Chengdu Nuodikang Biological Pharmaceutical Co., Ltd. Assignor: Keruide Pharmaceutical Co., Ltd., Sichuan Contract record no.: 2014510000018 Date of cancellation: 20151218 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 646000 national high tech Zone, Sichuan, Luzhou Province Pharmaceutical Industrial Park Patentee after: Sichuan Keruide pharmaceutical Limited by Share Ltd Address before: 646104 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee before: Keruide Pharmaceutical Co., Ltd., Sichuan |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Wu Shuying Document name: Decision of the request for invalidation |